No business profile yet.
Size EirGenix (6589.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $444M, the 466th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$51.50 on 18 Nov 2026.
Performance Over six months the shares gained 15.5%, against -10.7% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 57.8% over the last twelve months (peer median -2.2%); the operating margin is -50.7% (peer median -4.5%).
Valuation It trades at 9.9× enterprise value to sales against a peer median of 5.2× (7th most expensive of 15).
Capital Return on invested capital runs 12.7 points below its cost of capital (5.0% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.48B | NT$1.01B | NT$1.01B | NT$1.02B | NT$1.48B |
| Revenue growth | — | 0% | -1% | -31% | — |
| Gross profit | NT$643M | NT$64.4M | NT$56.1M | NT$118M | NT$661M |
| EBITDA | n/a | -NT$560M | -NT$652M | -NT$793M | -NT$126M |
| Net income | -NT$502M | -NT$761M | -NT$698M | -NT$915M | -NT$116M |
| Free cash flow | n/a | -NT$903M | -NT$1.23B | -NT$1.56B | -NT$491M |
| Capital expenditure | n/a | NT$1.62B | NT$928M | NT$775M | NT$820M |
| Total debt | n/a | NT$1.71B | NT$901M | NT$465M | NT$459M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6589.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | -12.7% | 4th highest of 21 |
| 6-month return | +15.5% | -10.7% | 4th highest of 19 |
| Distance from 52-week high | -38.9% | -39.7% | 10th highest of 21 |
| Revenue growth (TTM) | +57.8% | -2.2% | 4th highest of 16 |
| Operating margin | -50.7% | -4.5% | 6th lowest of 16 |
| EV / Sales | 9.9× | 5.2× | 7th most expensive of 15 |
| ROIC minus cost of capital | -12.7 pp | -6.0 pp | 5th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |